Medtech's Investing Climate

Originally Published MX July/August 2005

FINANCE

Medical technology executives still have some work ahead to heat up the interest of potential investors.

Barbara A. Wrigley

According to a national poll of leading medtech business executives and venture capitalists, the climate for medtech investing has definitely warmed up over the course of the past three years. And this year—with the steady decline of expectations for growth in pharmaceuticals continuing—expectations for growth in medical technology are solidly in the fields of medical devices and biotechnology.

Those were among the key results of the "2005 National Medtech Investing Survey" conducted this spring by the law firm of Oppenheimer Wolff & Donnelly LLP (Minneapolis) and MX magazine. This year's results mark the third appearance of this annual survey, which investigates investing trends in the medical technology marketplace. The trends that have become apparent over the course of three years indicate that medtech executives and investors remain optimistic about the opportunities for investing in medtech start-ups.